Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01356485
Other study ID # SCD-105
Secondary ID
Status Completed
Phase Phase 1
First received May 17, 2011
Last updated August 15, 2013
Start date January 2012
Est. completion date December 2012

Study information

Verified date August 2013
Source Sangart
Contact n/a
Is FDA regulated No
Health authority Jamaica: Ministry of HealthUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyFrance: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

Sickle Cell Anemia is caused by an inherited hemoglobin disorder. Healthy red blood cells are discoid and can deform and move through small blood vessels to carry oxygen to all parts of the body. In sickle cell disease, as red blood cells circulate and oxygen is released in the circulatory system, the deoxygenated abnormal hemoglobin S can begin to polymerize. When this occurs, the red blood cells can become sticky and elongated. These sickled red blood cells are less flexible and will obstruct small blood vessels and block normal red blood cells from traveling through the circulatory system, which limits oxygen delivery to tissues and organs. This is known as a "sickle crisis".

Patients suffering from a sickle crisis experience severe pain and are at risk of stroke, heart attack or even death. By lowering the level of oxygen pressure at which sickling occurs and opening the vasculature and rapidly delivering oxygen directly to ischemic tissues, the addition of MP4CO to existing treatment protocols may alleviate pain associated with a sickle cell crisis, abort a crisis and/or potentially reduce the duration of a crisis. This could mean less time in the hospital and an improved quality of life for patients with sickle cell anemia.


Description:

To date, no specific agent has been approved to treat sickle cell crisis, to reduce the severity of a sickling crisis, or to shorten the duration of admission. Current therapy for a sickling crisis is limited to hydration and symptomatic pain relief with opiates when pain is severe enough to cause admission to hospital. Administration of oxygen by inhalation alone has not proven effective. Carbon monoxide (CO) binds to Hb S and, while attached, prevents and reverses polymerization of Hb S chains and consequent distortion of the red blood cell. Carbon monoxide at very low doses also acts as a messenger to cells, reducing inflammation, reducing oxygen requirements, and preventing programmed cell death (apoptosis).

The MP4 molecule can be modified to carry CO and other gases to enhance therapeutic benefit for certain patients. MP4CO is therefore designed to deliver therapeutic, non-toxic levels of CO, to provide an immediate metabolic signal to cells and to reduce inflammation. Once the CO is released from the compound, the MP4 molecule gets oxygenated in the lung and then delivers oxygen to ischemic tissues.

Previously published studies provide a good foundation to postulate that a chemically modified hemoglobin such as MP4CO might have the ideal properties as an oxygen therapeutic agent for treatment or reversal of a sickling crisis. The initial release of CO from MP4CO is predicted to have a therapeutic effect including immediate stabilization of Hb S to prevent further polymerization and reverse existing sickling, vasodilation of capillaries, and anti-inflammatory properties. The subsequent circulation of the MP4 molecule as an oxygen therapeutic agent (after converting to MP4OX following oxygenation in the lungs) will help to 1) preferentially oxygenate ischemic cells, 2) reverse partially sickled red cells, and 3) improve oxygenation of local tissues, thereby potentially ameliorating the painful VOC caused by red blood cell sickling. In addition, MP4CO has enhanced chemical stability, which enables storage at room temperature while minimizing methemoglobin formation.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date December 2012
Est. primary completion date December 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Adult male or female patients (18 years of age or older) with diagnosed sickle cell disease based on Hb SS, or S/ß0 Thalassemia genotype, who are clinically stable and not experiencing an acute episode of pain

Exclusion Criteria:

- At least 4 painful VOCs within the preceding year requiring hospital treatment

- Urgent care facility, hospital treatment or admission for treatment of a painful VOC within the previous 2 months

- History of a painful VOC lasting longer than 2 weeks or > 12 pain episodes requiring intervention in a medical facility (emergency room, urgent care or clinic) in preceding year

- Baseline VAS pain score = 4 cm

- Hemoglobin < 6 g/dL

- Transfusion of packed red blood cells within previous 4 weeks

- Currently on iron chelation therapy

- History of sickle cell disease-attributed CNS disease (including a) recent or past history of stroke; b) ongoing treatment with chronic transfusion therapy to prevent stroke; c. history of seizures or epilepsy; and d. evidence of or known overt cerebral vasculopathy or known cerebral vessel narrowing

- Evidence of pulmonary hypertension, based on an estimated systolic pulmonary artery pressure > 25 mmHg calculated from TRJ velocity from a transthoracic echocardiography (TTE) assessment at Screening visit or from a previous TTE assessment if it was done within 1 year prior to randomization

- Baseline oxygen saturation by pulse oximetry = 90%

- History of a priapism within the last year

- History of hypertension requiring anti-hypertensive therapy

- Baseline bradycardia (heart rate < 60/min)

- History of myocardial infarction, myocardial ischemia, or angina

- Renal dysfunction or creatinine level within past 6 weeks of = 1.2 mg/dL (= 106 µmol/L) or a urine protein/creatinine ratio (PCR) > 50 mg/mmol

- Hepatic dysfunction (AST or GGT > 3x ULN, or ALT >2x ULN, or conjugated bilirubin > 2x patient's baseline within the last 6 weeks)

- Positive pregnancy test

- Any acute or chronic condition which would limit the patient's ability to complete the study

- Evidence of, or known to be chronically abusing illegal drugs or excessive quantities of alcohol

- Known to have HIV, or active Hepatitis B or C infection, or tuberculosis

- Received any other investigational drug(s) within 30 days prior to randomization

- Professional or ancillary personnel involved with this study or in the employment of the investigator

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)


Intervention

Drug:
MP4CO
43 mg/mL pegylated carboxyhemoglobin [= 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
Sodium chloride solution
Normal saline (0.9% sodium chloride solution)

Locations

Country Name City State
France Hôpital Henri Mondor Creteil
Jamaica Sickle Cell Unit, University of West Indies Kingston
Lebanon Rafic Hariri University Hospital Beirut
United Kingdom Guy's Hospital London
United Kingdom King's College London London

Sponsors (1)

Lead Sponsor Collaborator
Sangart

Countries where clinical trial is conducted

France,  Jamaica,  Lebanon,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary No efficacy evaluations will be made in this safety study 28 days No
Secondary Adverse events From 0 hrs after dosing through 28 Day Follow-up visit Yes
Secondary Vital signs Blood pressure, heart rate, respiration, temperature Baseline, Hourly from 0 - 8 hours, 24, 48, and 72 hours, and at 7 days Yes
Secondary Laboratory assessments Hematology, serum chemistry, urinalysis, renal function and biomarkers Baseline, 24, 48, and 72 hours, and at 7 days Yes
Secondary Pain levels Patient self-assessment of pain levels using Visual Analogue Scale Baseline, Hourly from 0 - 8 hours, 24, 48, and 72 hours, and at 7 days No
Secondary Pulmonary artery pressure assessment Trans-thoracic Echocardiography (TTE) Baseline, Pre-infusion, 1 hour post-infusion Yes
See also
  Status Clinical Trial Phase
Completed NCT02227472 - Working Memory and School Readiness in Preschool-Aged Children With Sickle Cell Disease
Recruiting NCT06301893 - Uganda Sickle Surveillance Study (US-3)
Recruiting NCT04398628 - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed NCT02522104 - Evaluation of the Impact of Renal Function on the Pharmacokinetics of SIKLOS ® (DARH) Phase 4
Recruiting NCT04688411 - An mHealth Strategy to Improve Medication Adherence in Adolescents With Sickle Cell Disease N/A
Terminated NCT03615924 - Effect of Ticagrelor vs. Placebo in the Reduction of Vaso-occlusive Crises in Pediatric Patients With Sickle Cell Disease Phase 3
Not yet recruiting NCT06300723 - Clinical Study of BRL-101 in Severe SCD N/A
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Completed NCT04134299 - To Assess Safety, Tolerability and Physiological Effects on Structure and Function of AXA4010 in Subjects With Sickle Cell Disease N/A
Completed NCT04917783 - Health Literacy - Neurocognitive Screening in Pediatric SCD N/A
Completed NCT02580565 - Prevalence of Problematic Use of Equimolar Mixture of Oxygen and Nitrous Oxide and Analgesics in the Sickle-cell Disease
Recruiting NCT04754711 - Interest of Nutritional Care of Children With Sickle Cell Disease on Bone Mineral Density and Body Composition N/A
Completed NCT04388241 - Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD N/A
Recruiting NCT05431088 - A Phase 2/3 Study in Adult and Pediatric Participants With SCD Phase 2/Phase 3
Completed NCT01158794 - Genes Influencing Iron Overload State
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Withdrawn NCT02960503 - Macrolide Therapy to Improve Forced Expiratory Volume in 1 Second in Adults With Sickle Cell Disease Phase 1/Phase 2
Withdrawn NCT02630394 - A Pilot Study of Azithromycin Prophylaxis for Acute Chest Syndrome in Sickle Cell Disease Phase 1
Completed NCT02567695 - A Single-Dose Relative Bioavailability Study Of GBT440 300 mg Capsules in Healthy Subjects Phase 1
Not yet recruiting NCT02525107 - Prevention of Vaso-occlusive Painful Crisis by Using Omega-3 Fatty Acid Supplements Phase 3

External Links